Next week, we will attend the ELRIG´S THERAPEUTIC OLIGOS & EUROPEAN CHEMICAL BIOLOGY SYMPOSIUM 2023 (ECBS2023) in Gothenburg, Sweden, co-organized by ELRIG and EU-OPENSCREEN/EuChemS, and hosted by AstraZeneca R&D site. The conference will focus on topics like Therapeutic OLIGO profiling, Advancements in OLIGO design and synthesis, Novel formulations and biomarker analysis, Chemical probe-induced protein interaction and degradation, New ways to shape and interrogate biology through chemistry, and innovative tools and methods for advanced cell profiling.
We will present one talk and two posters at the conference. The talk with the title Identification of novel inducers of erythropoiesis by high-content screening will be presented by Petr Bartůněk, the director of CZ-OS, on Thursday afternoon, as a part of the Innovative tools and methods for advanced cell profiling section. Concerning the posters, the first one was created by Martin Popr, the head of the compound management and automation at CZ-OS, and describes our AUTOMATED COMPOUND MANAGEMENT PIPELINE AT THE CZ-OPENSCREEN; the second one, by Ctibor Škuta, the head of the cheminformatics and software development, presents the European Chemical Biology Database (ECBD, ecbd.eu), developed and managed by CZ-OS, and its state in 2023.
Next week on 24th of May, we are going to present the Probes & Drugs portal at the prestigious conference Modern phenotypic drug discovery: From chemical biology to therapeutics in Denver, Colorado, organized by the Keystone Symposia on Molecular and Cellular Biology organization. In a short talk, we are going to present the current state of the portal under the title Probes & Drugs portal in 2022: A hub for the integration of high-quality bioactive compound sets, followed by a poster with the same name.
PDD as an approach to drug discovery and chemical biology has been building momentum and excitement in both academia and industry. The convergence of new technology platforms (e.g., induced pluripotent stem cells, CRISPR-Cas9 gene editing, 3D biology, advanced imaging) with other disciplines such as cheminformatics, machine learning, and artificial intelligence have led to an exciting renaissance of PDD. This meeting will bring together researchers performing or interested in phenotypic drug discovery (PDD) from across academia and industry.
Probes & Drugs (P&D) portal (probes-drugs.org) was released in 2017 to address the problems in the field of chemical probes and other high-quality chemical tools, concerning mainly the fragmentation and obsoleteness of the available data. Since then, it has become one of the major and most comprehensive resources in the field that serves as a hub for the integration of high-quality bioactive compound sets. Apart from the data integration, P&D recently established its own approach to evaluating the probe-likeness of compounds labelled as chemical probes (so-called probe-likeness score) and a live set of high-quality chemical probes (utilizing the score in combination with other key criteria), updated with each new version of P&D. As of ver. 04.2021, this set contains 620 compounds covering 496 primary targets. The synergy between integrated data sources and tools available for their analysis makes P&D a unique discovery platform designated not only for experts in the field of chemical biology but for a wider scientific community with limited knowledge in this area.